Moderna: Moderna's mRESVIA vaccine gains Health Canada approval
Moderna has received Health Canada's approval for its respiratory syncytial virus messenger ribonucleic acid (mRNA) vaccine mRESVIA, designed to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals aged 60 and over.
Read full article »
Moderna is a Massachusetts-based biotechnology company that researches and develops mRNA therapeutics for the treatment of cardiovascular and autoimmune diseases.
Read more